Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 24 2018 - 4:01PM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical
company focused on developing and commercializing novel antibiotics
to treat life-threatening multidrug-resistant (MDR) infections,
today announced that President and Chief Executive Officer Guy
Macdonald will present a corporate overview at the Cantor Global
Healthcare Conference on Monday, October 1, 2018 at 5:15 p.m.
Eastern Time at InterContinental New York Barclay Hotel in New York
City.
A live webcast of the presentation will be
available on the Company’s website at
http://ir.tphase.com/events.cfm. The archived presentation will be
available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for
serious and life-threatening bacterial infections, including those
caused by many of the multidrug-resistant bacteria highlighted as
urgent public health threats by the World Health Organization and
Centers for Disease Control and Prevention. The Company has created
more than 3,000 novel tetracycline compounds using its proprietary
technology platform. Tetraphase's pipeline includes three
antibiotic clinical candidates: XERAVATM, TP-271 and TP-6076.
XERAVA is approved by the U.S. Food and Drug Administration and the
European Medicines Agency for the treatment of complicated
intra-abdominal infections. TP-271 and TP-6076 are in phase 1
clinical trials. Please visit www.tphase.com for more company
information.
Media and Investor
Contact:Tetraphase PharmaceuticalsJennifer
Viera617-600-7040jviera@tphase.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024